Clinical Trial Update: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2, Phase 3]

View source ↗

Summary

This Phase 2/Phase 3 trial compares Livmoniplimab plus Budigalimab with chemotherapy versus Pembrolizumab plus chemotherapy as first-line treatment for untreate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Livmoniplimab
• Pembrolizumab (pembrolizumab)
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING